<DOC>
	<DOC>NCT02040623</DOC>
	<brief_summary>- To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. - To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.</brief_summary>
	<brief_title>Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Received an Allogeneic hematologic stem cell transplantation at least 3 months prior. Subjects with post Allogeneic hematologic stem cell transplantation onset or worsening of dry eye symptoms for at least 1 month prior. Use of overthecounter and/or prescription eye drops for dry eye symptoms within 1 month. Corneal fluorescein staining score of ≥ 2 in 1 region and ≥ 1 in at least 1 other region. Total lissamine green conjunctival staining score (according to a modified National Eye Institute grading system) of ≥ 2. Clinically unstable Graft versus Host Disease (requiring a change in immunosuppressive regimen), medical condition, or laboratory abnormality Used topical ophthalmic cyclosporine within 45 days. Used any topical ophthalmic steroid within 2 weeks. Used autologous serum eye drops within 2 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Graft versus Host Disease</keyword>
	<keyword>Keratoconjunctivitis Sicca</keyword>
</DOC>